The company behind a search agent to assist clinical decision-making – OpenEvidence – has raised an impressive $210 million ...

Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and artificial intelligence to drug safety monitoring and risk management.

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

From dissecting clinical updates to identifying novel targets beyond NLRP3, this summit brings together the brightest minds transforming the field of innate immunity and inflammation.

At ASCO 2025, Johnson & Johnson contributed more than 70 abstracts, reflecting the depth of their oncology portfolio, and commitment to redefining what’s possible for a wide range of solid tumour and ...

Draft guidance from reimbursement authority NICE has recommended use of the artificial intelligence technologies – Aidoc ...

Developing new biomarker assays is highly specialised work. It requires careful screening of antibody pairs, sensitivity and ...

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March, 2029, with company chairman Norbert Winkeljohann saying: "We're starting to ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives, namely ...